[Expert consensus on clinical localization detection standards for metagenomic next generation sequencing of pathogens].

Infectious diseases seriously endanger human health. Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases. Traditional pathogen testing techniques cover a limited variety of microorganisms, making it difficult to meet clinical needs. Metagenomic Next Generation Sequencing (mNGS) theoretically can simultaneously detect all known gene sequences of pathogens, greatly improving the clinical capacity of diagnosing and treating patients with severe, complicated, rare, and emerging pathogen infections. In the context of individualized health needs, the self-built testing of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment. Due to the high starting point of research and development and the complex operation process of the mNGS technology platform, this study reaches a consensus on the experimental procedure, assay validation, quality control, and report review of the mNGS-LDT in the fields of clinical testing, infection, critical care, and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.感染性疾病严重危害人类生命健康，快速准确检测病原体是有效治疗和精准防控感染性疾病的关键环节。传统的病原学检验技术覆盖的微生物种类少，难以满足临床需求。宏基因组高通量测序（mNGS）理论上可同时检测所有已知基因序列的病原体，在很大程度上提高了临床疑难危重感染、罕见和新发病原体感染的诊断水平和救治能力。在个体化医疗需求的大背景下，新技术的实验室自建检测能够持续提高临床诊治水平。由于mNGS技术平台研发起点高、操作流程复杂，为了保证该技术合理应用，保障患者医疗安全，本文在临床检验、感染、危重症及体外诊断等领域的专家就mNGS-LDT的流程搭建、性能确认、质量控制、报告审核等方面形成共识并提出规范要求和建议。.